$MESO News

Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil

Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

Mesoblast Reports Substantial Revenue Growth to US$120M

Mesoblast H2 Earnings Call Highlights

Full Transcript: Mesoblast FY 2026 Earnings Call

Mesoblast Financial Results and Corporate Update Webcast

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment

Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026